BIO-LES Business Development Fundamentals Course Faculty

  • Recommend
  • Tweet
  • Print
  • Email

2014 Business Development Fundamentals Course Faculty

This page shows the 2014 Business Development Fundamentals course faculty members. We also offer an Advanced Business Development course- click here to view the Advanced Business Development faculty.

Anjan Aralihalli
Senior Director, Business Development, Shiongi Inc.

Anjan or "AJ" Aralihalli has close to 20 years of pharmaceutical industry experience in Canada and the US in a variety of functions (clinical development, finance, sales, marketing and business development). He has worked in both big pharma and biotech and, after eight years at Sanofi-Aventis, recently joined the US office of Shionogi, a Japanese pharmaceutical company.

C. Peter Giuliano
Founder & Chairman, ECG

Peter Giuliano is founder and Chairman of ECG, the communication strategy company. Over more than two decades, Peter and ECG President Frank J. Carillo have guided the firm to a leadership position in its field through their use of proprietary teaching methods and their broad-based communication expertise.

For 21 years, Peter has worked with CEOs, managers and professional staffs of companies ranging from large multinationals to recent startups. His clients have included some of the world’s top corporations, among them Unilever, TRW, Computer Sciences Corporation, Corning Incorporated, The World Bank, Roche Pharmaceuticals and The Associated Press. He has also been a consultant and trainer to a number of government agencies, including the US Department of Commerce, The Federal Reserve Board, The FBI, The International Finance Corporation division of the World Bank, the Veterans Administration, and the Federal Quality Institute, and he has counseled and trained executives of major trade and professional associations in the U.S. and Europe.

Peter credits his background in theater, combined with his business and training experience, as a key factor in his ability to develop in his clients a more effective communications and leadership style.

Karl Handelsman
Founder, Codon Capital

Karl is a seasoned venture capitalist with over 15 years of experience investing in early stage biotechnology. Karl has worked with entrepreneurs from Idea to IPO as a trusted advisor and BOD member. Prior to his role as a venture capitalist he worked in business development at biotech companies which were acquired for billions of dollars. Karl was a sponsor of the first Synthetic Biology conference at MIT. Karl founded Codon Capital last year with a focus on early stage bio-innovation.

Richard A. Hoffman
Partner, WilmerHale

Mr. Hoffman is a seasoned lawyer, consultant and entrepreneur in the life sciences industry, and has significant experience in establishing new companies, negotiating and closing venture capital financings, in-licensing technologies, and developing and implementing corporate and business development strategies. Mr. Hoffman also has a successful track record in structuring, negotiating, and documenting strategic deals with both public and private companies.

From 1998 until 2013, Mr. Hoffman dedicated himself to pursuing entrepreneurial endeavors, serving as a legal advisor and business consultant to numerous biotech companies. Most recently, Mr. Hoffman was principal at R.A. Hoffman Consulting, which provided entrepreneurs and early-stage biotechnology, medical device and health care information companies with advice on corporate and business development strategies and tactics.

Mr. Hoffman began his career as an associate and, later, as junior partner at Hale and Dorr LLP. He worked in the corporate group from 1987 through 1994, representing biotechnology and medical device companies in public offerings, collaborative research arrangements, strategic alliances, intellectual property licensing and venture capital financings. In 1994, he became vice president of Finance and Business Development at Hybridon, Inc. (now a public company, Idera Pharmaceuticals) and later served in a similar role at biotech company Avitech, Inc.

Neel Patel
Practice Executive, Campbell Alliance

Neel Patel brings to Campbell Alliance more than 15 years of experience advising companies primarily focused in life-sciences and healthcare. He has a broad network in the life-sciences private equity community, management consulting, corporate development, and transaction advisory work. Mr. Patel has completed regional and cross-border M&A, licensing, and financing transactions for biotech and large pharma companies, and has over eight years of management consulting experience with clients across several industries to improve their competitive positions through a combination of growth, cost-cutting, and asset effectiveness initiatives.

Before joining Campbell Alliance, Mr. Patel was a member of Burrill & Company’s Merchant Banking Group where he managed strategic transactions for clients through advisory work. Transactions included mergers and acquisitions, partnering/licensing, and financing. Prior to that role, Mr. Patel was a management consultant with AT Kearney and Mercer Management Consulting. His experience includes strategy and operations consulting to international corporate clients in Pharmaceuticals, Biotech, Healthcare, Diagnostics, High Tech, and Consumer Goods.

Jake Schaible
President, Toscana Ventures, Inc.

Toscana Ventures, Inc. is a boutique New Venture / Business Development Consultancy based in San Diego, California. The firm focuses on the incubation of new BioPharma venture concepts, as well as assisting other emerging biopharmaceuticals with their own fundraising and transactional support needs.

John Selig

John Selig, Esq
Managing Director, Woodside Capital Partners

John Selig is a Managing Director and co-head of the Life Sciences Group at Woodside Capital Partners. He advises companies on M&A, licensing and finance strategy.

Prior to joining Woodside, he was a Partner at Keelin Reeds Partners, a life sciences management consulting firm, where he advised dozens of VC-backed and small cap biopharmaceutical, medical device and diagnostics companies on M&A and licensing strategies, portfolio management, valuation and strategic direction. While at KR, John led a partnership deal term benchmarking effort and has extensive experience in applying that data to yield market-value deal terms for dozens of assets, using the results to inform product strategy and to provide ongoing support during deal negotiations. John also combined his expertise in valuation, deal term benchmarking and decision analysis with his background in law to help companies make optimal decisions in litigation and settlement.

Previously, John was a senior consultant with Strategic Decisions Group, a global management consulting firm, where he advised numerous Fortune 500 companies in life sciences and other industries on valuation, business strategy and M&A. Prior to consulting, John was an attorney with Weil, Gotshal & Manges LLP where he focused on M&A and corporate finance.

John holds a JD from Stanford Law School and a BA from Brown University.

Robert Silverman, J.D., Ph.D.
Senior Vice President and General Counsel, Concert Pharmaceuticals , Inc.

Robert Silverman, J.D., Ph.D. has served as Concert Pharma's Senior Vice President and General Counsel since December 2010 and prior to that was Convert Pharma's Vice President and General Counsel from January 2007 to December 2010. Prior to joining Concert, he served in various legal related roles at Millennium Pharmaceuticals, Inc., a pharmaceutical company, Vertex and FMC Corporation, a chemical manufacturing company. Dr. Silverman received his J.D. from Rutgers-Camden Law School, a Ph.D. in organic chemistry from the University of New Mexico and a B.A. from Lehigh University.

Patricia Sinatra

Patricia Sinatra
Managing Director, Vector Strategic Advisors

Since 2006, Patricia has organized and served as faculty for the BIO/LES Business Development Basics Course. She has more than 20 years of licensing and commercial drug development experience and is currently the Managing Director at Vector Strategic Advisors which provides licensing and strategic advisory services for small and sized biopharma companies. Prior to Vector, Pat served as Vice President of Business Development and Corporate Strategy for Telome Health Inc, and VP of Business Development and Commercial Strategy for Sutro Biopharma, Inc.  Previously, Pat was Sr. Director of Business Development and Alliance Management for Dynavax Technologies, and was Director of Business Development at Abgenix, where in addition to her licensing and alliance management responsibilities she managed strategic marketing initiatives for the company’s oncology and inflammation portfolio. She also held positions of increasingly responsibility for Matrix Pharmaceutical, ALZA (formerly SEQUUS®) Pharmaceuticals, FCB Healthcare, SmithKline Beecham plc, and Fujisawa-SmithKline Pharmaceuticals.

Pat conducted post-graduate doctoral level studies in microbiology at the University of Texas Southwestern Graduate School of Biomedical Sciences and has a B.S. degree in biology from the State University of New York.

Kenneth Weber, PhD
Kilpatrick Townsend & Stockton LLP

Kenneth Weber, PhD, focuses his practice on patent prosecution, particularly in the areas of molecular genetics, chemistry, pharmaceuticals, plant science, medical devices and microbial genetics. He regularly assists clients in patent portfolio management, due diligence reviews, validity/infringement opinions and licensing.

Dr. Weber's clients include public and private corporations across the United States. Representative corporate clients include Aqua Bounty Technologies; Avanir, Inc.; Biosensors International; and Corcept Therapeutics, Cepheid, Inc., Ciphergen Biosystems, Inc. and Sutro Biopharma based in California. Ken is a member of the American Bar Association and the American Intellectual Property Law Association. He received his J.D. degree from the University of Washington and holds a PhD in Plant Pathology.